Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA

ALK Mutants in the Kinase Domain Exhibit Altered Kinase Activity and Differential Sensitivity to Small Molecule ALK Inhibitors†̈

(2009) Lihui Lu et al.   BIOCHEMISTRY

The Aryl Hydrocarbon Nuclear Translocator Alters CD30-Mediated NF- B-Dependent Transcription

(2009) C. W. Wright et al.   SCIENCE

Anaplastic Lymphoma Kinase (ALK)-Induced Malignancies: Novel Mechanisms of Cell Transformation and Potential Therapeutic Approaches

(2009) Mariusz A. Wasik et al.   SEMINARS IN ONCOLOGY

Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family

(2008) Andrew M. Evens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting STAT3 in cancer: how successful are we?

(2008) Peibin Yue et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phosphorylated VEGFR2/KDR receptors are widely expressed in B-cell non-Hodgkin's lymphomas and correlate with hypoxia inducible factor activation

(2008) Alexandra Giatromanolaki et al.   HEMATOLOGICAL ONCOLOGY

Signal Transducer and Activator of Transcription 3 Is Required for Hypoxia-Inducible Factor-1  RNA Expression in Both Tumor Cells and Tumor-Associated Myeloid Cells

(2008) G. Niu et al.   MOLECULAR CANCER RESEARCH

Histological expression of angiogenic factors: VEGF, PDGFRα, and HIF-1α in Hodgkin lymphoma

(2008) Freda H. Passam et al.   PATHOLOGY RESEARCH AND PRACTICE

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy

(2007) Rongshi Li et al.   MEDICINAL RESEARCH REVIEWS